Molecular approaches to management of epithelial ovarian cancer

International Journal of Gynecological Cancer

Volumn 10, Issue SUPPL. 1, 2000, Pages 2-7

  Bast Jr , R C ^a   Yu, Y ^a   Xu, F J ^a   Le, X F ^a   Mills, G B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; EARLY DIAGNOSIS; FEMALE; GENE MUTATION; GENE THERAPY; HETEROZYGOSITY LOSS; HUMAN; OVARY CANCER; PATHOGENESIS; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 6744237787     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2000.99502.x     Document Type: Article

References (49)

1. Jacobs IJ, Kohler MF, Wiseman R et al. Clonal origin of epithelial ovarian cancer: analysis by loss of heterozygosity, p53 mutation and X chromosome inactivation. J Natl Cancer Inst 1992;84:1793-8.
2. Mok CH, Tsao WW, Knapp RC et al. Unifocal origin of advanced human epithelial ovarian cancer. Cancer Res 1992;52:5119-22.
3. Li S, Han H, Resnik E et al. Advanced ovarian carcinoma: molecular evidence of unifocal origin. Gynecol Oncol 1993;51:21-5.
4. Lu KH, Bell DA, Welch WR, Berkowitz RS, Mok SC. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors. Cancer Res 1998;58:2328-30.
5. Schorge JO, Muto MO, Welch WR et al. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. J Natl Cancer Inst 1998;90:841-5.
6. Berchuck A, Kohler MF, Hopkins MP et al. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. Gynecol Oncol 1994;52:232-6.
7. Gershenson DM, Deavers M, Diaz S et al. The prognostic significance of p53 expression in advanced stage ovarian serous borderline tumors. Clin Cancer Res, in press.
8. Kohler MF, Marks JR, Wiseman RW et al. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 1993;85:1513-9.
9. Stanford JL. Oral contraceptives and neoplasia of the ovary. Contraception 1991;43:543-56.
10. Schildkraut J, Bastos E, Berchuck A. Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst 1997;89:932-8.
11. Righetti SC, Della Torre G, Pilotti S et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996;56:689-93.
12. Hagopian GS, Mills GB, Khokhar AR et al. Studies of cisplatin (CDDP) resistance with 1R,2R-diaminocyclohexane (DACH)-diacetato-dichloro-Part (IV) (acetato-Part) in ovarian cancer cell lines. Clin Cancer Res 1999;5:655-64.
13. Mujoo K, Maneval DC, Anderson SC, Gutterman JU. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene 1996;12:1617-23.
14. von Gruenigen VE, Santoso JT, Coleman RL et al. In vivo studies of adenovirus-based p53 gene therapy for ovarian cancer. Gynecol Oncol 1998;69:197-204.
15. Wolf JK, Mills GB, Bast RC Jr et al. Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogneous p53 status. Gynecol Oncol 1999;75: 261-6.
16. Heise C, Sampson-Johannes A, Williams A et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med 1997;3:639-45.
17. Bast RC Jr, Mills GB. The molecular pathogenesis of ovarian cancer. In: Mendelsohn J, Howley P, Israel M, Liotta L, eds. The Molecular Basis of Cancer, 2nd edn, in press.
18. Yu Y, Xu F, Fang X et al. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci USA 1999;96:214-9.
19. Nagai H, Negrini M, Carter SL et al. Detection and cloning of a common region of loss of heterozygosity at chromosome 1p in breast cancer. Cancer Res 1998;55:1752-7.
20. Loupart ML, Armour J, Walker R, Adam S, Brammar W, Varley J. Allelic imbalance on chromosome 1 in human breast cancer. I minisatellite RFLP analysis. Genes Chromosomes Cancer 1995;12:16-23.
21. Hoggard N, Brintnell B, Howell A, Wissenbach J, Varley J. Allelic imbalance on chromosome 1 in breast cancer. II. Microsatellite repeat analysis. Genes Chromosomes Cancer 1995;12:24-31.
22. k gene in a human ovarian carcinoma. Science 1984;223:698-701.
23. Enomoto T, Inoue M, Perantoni AO et al. K-ras activation in neoplasms of the human female reproductive tract. Cancer Res 1990;50:6139-45.
24. Patton SE, Martin ML, Nelson LL et al. Activation of the Ras-MAP pathway and phosphorylation of ets-2 at position threonine 72 in human ovarian cancer cell lines. Cancer Res 1998;58:2253-9.
25. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989;244:707-12.
26. Berchuck A, Kamel A, Whitaker R et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50: 4087-91.
27. Rubin SC, Finstad CL, Federici MF et al. Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer. Cancer 1994;73:1456-9.
28. Xu F-J, Yu YH, Le X-F et al. The outcome of heregulin induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression. Clin Cancer Res 1999;5:3653-60.
29. c-erbB2: Increased invasiveness may contribute to poor prognosis. Clin Cancer Res 1997;3:1629-34.
30. Yu Y, Matin A, Xia W. Liposome-mediated in vivo E1A gene transfer suppressed growth of ovarian cancer cells that overexpress HER-2/neu. Oncogene 1995;11:1383-8.
31. Ueno NT, Hung MC, Zhang S. Phase 1 E1A gene therapy in patients with advanced breast and ovarian cancers. Proc Am Soc Clin Oncol 1998;17:432a.
32. Xu FJ, Lupu R, Rodriguez GC et al. Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. Int J Cancer 1993;53:401-8.
33. Le X-F, McWatters A, Wiener J, Wu J-W, Mills GB, Bast RC Jr. Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms. Clin Cancer Res, in press.
34. Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, Kumar R. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem 1998;237:28238-46.
35. Baselga J, Tripathy D, Mendelsohn J et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patient with HER2/ neu-overexpressing metastatic breast cancer. J Clin Onc 1996;14:737-44.
36. Slamon D, Leyland-Jones B, Shak S et al. Addition of herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized multinational controlled phase II trial. Proc Am Soc Clin Oncol 1998;17:98 (A#377).
37. Nicholson S, Gooden CS, Hird V et al. Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis. One Report 1998;5:223-6.
38. Xu FJ, Boyer CM, Bae DS et al. The tyrosine kinase activity of the c-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin A chain immunotoxin. Int J Cancer 1994;59:242-7.
39. Weis W, Harwerth JM, Mueller M et al. Selective inhibition of tumor cell growth by recombinant single chain antibody toxin specific for the erbB-2 receptor. Cancer Res 1992;52:6310-7.
40. Shayesteh L, Lu Y, Kuo WL et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nature Genet 1999;21: 99-102.
41. Hu L, Saloudek C, Mills G, Gray J, Jaffe RB. Effects of a PI3 kinase inhibitor (LY294002) on growth of ovarian carcinoma in vivo and in vitro. Clin Cancer Res 1999 in press.
42. Karlan BY. Screening for ovarian cancer: what are the optimal surrogate endpoints for clinical trials? J Cell Biochem 1995;23(Suppl):227-32.
43. Bast RC Jr, Siegal FP, Runowicz C et al. Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma. Gynecol Oncol 1985;22:115-20.
44. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989;4:1-12.
45. Skates SJ, Xu FJ, Yu Y et al. Toward an optimal algorithm for ovarian cancer screening longitudinal tumor markers. Cancer 1995;76:2004-10.
46. Rosenthal A, Jacobs I. Ovarian cancer screening. Semin Oncol 1989;25:315-25.
47. Woolas RP, Xu FJ, Jacobs IJ et al. Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst 1993;85:1748-51.
48. Xu Y, Zhongzhou S, Wiper D, Wu M et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998;280:719-23.
49. Zhang Z, Barnhill SD, Xu FJ et al. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol Oncol 1999;73:56-61.